An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
This study is for baby boys younger than 9 months who have a serious inherited condition called Ornithine Transcarbamylase (OTC) deficiency. This condition means their body struggles to get rid of a harmful substance called ammonia, which can cause severe health problems. The study is testing a new gene therapy called ECUR-506. Gene therapy aims to fix the faulty gene causing the problem. Researchers want to see if ECUR-506 is safe, how well it works, and what dose is best. It's an early phase study, meaning it's one of the first times this treatment is being tested in people. The hope is to find a new way to help babies with this condition.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
OTC deficiency is a challenging condition where a baby's body can't process certain waste products properly, leading to a build-up of a toxic substance called ammonia. This build-up can be very dangerous, causing brain damage, coma, and even death if not managed. This condition is inherited and is often more severe in baby boys, appearing shortly after they are born. Current treatments involve special diets and medications, but researchers are always looking for better options.
This study is investigating a new treatment called ECUR-506. It's a type of gene therapy, which means it aims to address the root cause of OTC deficiency – a faulty gene. ECUR-506 works by trying to put a working copy of the missing gene into the liver cells. This working gene would then help the body process ammonia correctly. The therapy is given as a single infusion into a vein.
The main goals of this study are to find out if ECUR-506 is safe for babies, what side effects it might have, and if it helps to improve their condition. It's also looking at different doses to see which one works best. This type of study is an early step in developing new medicines, aiming to gather important information before it can be made widely available.
النقاط الرئيسية
- Targets severe OTC deficiency in baby boys.
- Investigates a new gene editing therapy called ECUR-506.
- Aims to replace the faulty gene causing the condition.
- It's an early-stage study focused on safety and dosage.
- A single treatment given by IV infusion.
من قد يكون مؤهلاً؟
This study is specifically looking for baby boys who are between 24 hours and 7 months old and weigh between 3.5 kg and 13.5 kg. To join, a baby must have a confirmed diagnosis of severe OTC deficiency, meaning they had a very high ammonia level and symptoms shortly after birth. They should also be receiving the usual treatments for OTC deficiency, like a special diet and medications.
There are also some reasons why a baby might not be able to join. For example, babies who have serious birth injuries affecting their brain, or those needing a liver transplant soon, would not be eligible. If a baby has other serious health problems, such as major organ damage, or has already had gene therapy, they also wouldn't be able to take part. The study also needs parents or guardians who can understand and agree to the study requirements.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Is your baby a boy?
- Is your baby under 7 months old?
- Does your baby have severe OTC deficiency confirmed by a genetic test?
- Did your baby have very high ammonia levels soon after birth?
- Is your baby currently on a special diet and medication for OTC deficiency?
ماذا يتضمن المشاركة؟
We don’t have all the details about what participating involves, but generally, studies like this include regular hospital visits for check-ups, blood tests, and other assessments to monitor your baby's health and how the treatment is working. The study drug, ECUR-506, is given once as an infusion into a vein. There will be long-term follow-up to see how your baby is doing after the treatment. The total duration of participation isn't specified here, but gene therapy studies often involve monitoring for several years.
المخاطر والفوائد المحتملة
المواقع (12)
- UCLA Mattel Children's Hospitalالرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة
- Children's Hospital of Colorado, Anshutz Medical Campusالرمز البريدي المؤكدأورورا، الولايات المتحدة
- Emory University School of Medicineالرمز البريدي المؤكدأتلانتا، الولايات المتحدة
- مستشفى آن وروبرت إتش. لوري للأطفال في شيكاغوالرمز البريدي المؤكدشيكاغو، الولايات المتحدة
- كلية إيكان للطب في جبل سيناءالرمز البريدي المؤكدنيويورك، الولايات المتحدة
- جامعة أوريغون للصحة والعلومالرمز البريدي المؤكدبورتلاند، الولايات المتحدة
- The Children's Hospital at Westmeadالرمز البريدي المؤكدسيدني، أستراليا
- مستشفى الأطفال الملكيالرمز البريدي المؤكدملبورن، أستراليا
- Hopsital Sant Joan de Deuالرمز البريدي المؤكدبرشلونة، إسبانيا
- مستشفى جامعة 12 أكتوبرالرمز البريدي المؤكدمدريد، إسبانيا
- مستشفى جريت أورموند ستريتالرمز البريدي المؤكدلندن، المملكة المتحدة
- The Newcastle upon Tyne Hospitals NHS Foundation Trust- Great North Children's Hospitalالرمز البريدي المؤكدنيوكاسل أبون تاين، المملكة المتحدة
أسئلة شائعة
What is OTC deficiency?
It's a serious inherited condition where the body can't properly remove a harmful substance called ammonia, which can build up to dangerous levels.
ما هي العلاج الجيني؟
Gene therapy aims to correct genetic problems by introducing a working copy of a faulty gene into the body.
من يمكنه الانضمام إلى هذه الدراسة؟
Only baby boys under 7 months old with a severe type of OTC deficiency can be considered for this study.
How is the treatment given?
The gene therapy, ECUR-506, is given as a single treatment through a drip into a vein.
Will my baby still need their usual treatments?
Yes, babies in the study will continue to receive their standard treatments, such as special diets and scavenger medications.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.